Novo Nordisk cuts Wegovy prices in half for cash-paying consumers

Published On Mar 5, 2025, 12:46 PM

Novo Nordisk has halved the price of its weight-loss drug Wegovy to $499 per month for U.S. patients who pay cash through its online pharmacy. This change comes as competition in the weight-loss drug market intensifies, especially after the FDA confirmed that supply shortages have been resolved. The company has also recently indicated expectations of slower revenue growth in 2025 due to rising competition, which also prompted price cuts from competitors like Eli Lilly. Despite these challenges, Novo Nordisk's previous fiscal quarter showed revenues surpassing Wall Street expectations.

Stock Forecasts

NVO

Positive

Novo Nordisk's price cut for Wegovy aims to enhance accessibility and remain competitive, potentially increasing sales volume amid fierce market competition. This strategic move may attract more cash-paying customers and offset any negative perception from the anticipated slower revenue growth. Long-term demand for weight-loss drugs remains strong, especially as obesity awareness rises. However, increasing competition could pressure margins.

Related News

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past six months.Most Read from BloombergHow the 2025 Catholic Jubilee Is Reshaping RomeManhattan’s Morning Commute Time Drops With New Congestion TollTrump Paves the Way to Deputize Local Police on ImmigrationHousing Aid Uncertain After Trump’s Spending Freeze MemoTrump's Federal Funding Pause Th

Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.

NVO
BA
MSFT

Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.

MSFT
NVO
BA